Regulus Therapeutics Inc.
RGLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.05 | 0.02 | 0.04 |
| FCF Yield | -47.19% | -112.82% | -123.82% | -88.89% |
| EV / EBITDA | -1.11 | -0.09 | -0.11 | 0.95 |
| Quality | ||||
| ROIC | -65.26% | -131.96% | -71.37% | -43.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.89 | 0.90 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -53.44% | -5.77% | -6.19% | -94.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.83 | 0.69 | 0.64 | 1.95 |
| Interest Coverage | -316.71 | -51.50 | -41.05 | -32.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 7.03 | 0.04 | 0.15 |
| Cash Conversion Cycle | -996.12 | 48.42 | 8,481.76 | 2,166.94 |